Samsung Biologics to Acquire PolyPeptide for $1.8 Billion to Enter Peptide Manufacturing Sector

1. Samsung Biologics launched a $1.8 billion all-cash bid to acquire 100% of PolyPeptide, expanding into the peptide sector. Newsworthy Reliable Very positive
2. The deal is expected to complete by the end of 2026, marking the largest biopharmaceutical acquisition in Korea's history. Newsworthy Reliable Very positive
3. PolyPeptide is a Swiss multinational CDMO specializing in peptide and oligonucleotide active pharmaceutical ingredients with six global manufacturing sites. Newsworthy Reliable Neutral
4. PolyPeptide shareholders will receive approximately $54.91 in cash per share as per the offer on the SIX Swiss Exchange. Relevant Reliable Neutral
5. Peptides, including GLP-1 drugs for obesity, are a fast-growing segment valued at $140.9 billion in 2025, projected to reach $294.6 billion by 2033. Newsworthy Reliable Very positive
6. Samsung Biologics aims to enhance its multi-modality capabilities including peptides, oncology, and expand geographic presence in the US, Europe, and India. Newsworthy Reliable Very positive
7. PolyPeptide reported $271 million revenue in H1 2026, a 41.6% increase over the previous year, reflecting strong sales growth and profitability. Relevant Reliable Very positive
8. Samsung Biologics recently expanded US production capacity adding a New Jersey plant, bringing total capability to 845,000 liters. Relevant Reliable Very positive

Type: standard news · Analysis confidence: 95%

Used in syntheses

• Samsung Electronics America cuts 739 jobs moving HQ to Texas • TSMC accelerates $265 billion U.S. AI-driven chip expansion • ASML nears $700 billion valuation on AI demand • Nvidia faces Google and Moonshot AI competition • Micron drops 30% despite record AI earnings • Samsung Biologics acquires PolyPeptide for $1.8 billion • SK hynix warns of memory market risks amid $739 billion capacity expansion • Nvidia expands D.C. office, readies RTX Spark for Windows on Arm
• Samsung Electronics America cuts 739 jobs relocating HQ to Texas • TSMC accelerates $265B Arizona expansion amid AI chip demand • Samsung Biologics bids $1.8B for PolyPeptide • Micron shares fall 30% despite record AI-driven revenue • ASML stock up 60% in 2026, nearing €1 trillion valuation • Intel lowers FY2026 EPS forecast while advancing AI manufacturing • UFC's Alexandre Pantoja aims for flyweight title rematch after injury • NVIDIA leases 27,600 sq ft office in Washington D.C.